The Efficacy of 10-day and 14-day Bismuth-based Quadruple Therapy in First-line H. Pylori Eradication

PHASE4Enrolling by invitationINTERVENTIONAL
Enrollment

312

Participants

Timeline

Start Date

May 6, 2020

Primary Completion Date

July 31, 2028

Study Completion Date

July 31, 2028

Conditions
Helicobacter Pylori InfectionDysbiosisProbiotics
Interventions
DRUG

Bismuth Subcitrate 120 MG Oral Tablet

Bismuth Subcitrate (120 MG Oral Tablet) 1 tab per oral four times per day for 14 days in the14-day bismuth-based quadruple therapy and for 10 days in the10-day bismuth-based quadruple therapy

DIETARY_SUPPLEMENT

Lactobacillus acidophilus and Bifidobacterium lactis Bb12

"The probiotic powder per oral twice daily for 24 weeks. The probiotic powder is named as President AB powder, which contains an approximately equal mixture of Lactobacillus acidophilus and Bifidobacterium lactis Bb12 at a concentration of \>= 10E9 CFU/mL (President Corp., Tainan, Taiwan)."

DRUG

Esomeprazole 40mg

Esomeprazole (40 mg) 1 tab per oral twice per day for 14 days in the14-day bismuth-based quadruple therapy and for 10 days in the10-day bismuth-based quadruple therapy

DRUG

Metronidazole 250 MG

Metronidazole (250 MG) 2 tab per oral thrice per day for 14 days in the14-day bismuth-based quadruple therapy and for 10 days in the10-day bismuth-based quadruple therapy

DRUG

Tetracycline Pill

Tetracycline (250 MG) 2 tab per oral four times per day for 14 days in the14-day bismuth-based quadruple therapy and for 10 days in the10-day bismuth-based quadruple therapy

Trial Locations (1)

704302

Helicobacter pylori study group, National Cheng Kung University Hospital, Tainan City

All Listed Sponsors
lead

National Cheng-Kung University Hospital

OTHER